BLOG

Initial Results Positive For Valneva/Pfizer’s Lyme Disease Vaccine In First Phase II Study

Speciality vaccine biotech Valneva outlines seroconversion rates and safety of candidate Lyme disease vaccine that it is co-developing with partner Pfizer.